Title: Eli Lilly Leverages Camurus’ FluidCrystal Technology in a $870 Million Strategic Bid for the Long-Acting Obesity Market In a ground-breaking move to target the long-acting obesity market, pharmaceutical titan Eli Lilly has inked a hefty $870 million collaboration and licensing agreement with Swedish biopharmaceutical firm, Camurus AB. This high-stakes deal will see Lilly leveraging […]